RANI (Rani Therapeutics Holdings) OCF Margin %: -380.39% (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.74
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings OCF Margin %?

Rani Therapeutics Holdings RANI -3.22% 32 OCF Margin % is -380.39% as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 74.04% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Rani Therapeutics Holdings's Cash Flow from Operations for the three months ended in Mar. 2026 was $-6.50 Mil. Rani Therapeutics Holdings's Revenue for the three months ended in Mar. 2026 was $1.71 Mil. Therefore, Rani Therapeutics Holdings's OCF Margin % for the quarter that ended in Mar. 2026 was -380.39%.

As of today, Rani Therapeutics Holdings's current OCF Yield % is -20.51%.

The historical rank and industry rank for Rani Therapeutics Holdings's OCF Margin % or its related term are showing as below:

RANI' s OCF Margin % Range Over the Past 10 Years
Min: -3452.92   Med: -2683.04   Max: -1145.99
Current: -538.4

During the past 7 years, the highest OCF Margin % of Rani Therapeutics Holdings was -1145.99%. The lowest was -3452.92%. And the median was -2683.04%.

RANI's OCF Margin % is ranked worse than
74.04% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs RANI: -538.40

Rani Therapeutics Holdings OCF Margin % Related Terms

Rani Therapeutics Holdings OCF Margin % Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings OCF Margin % Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -1,186.79 0.00 0.00 -3,452.92 -1,145.99

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,737.79 0.00 0.00 20.12 -380.39

RANI vs CGTX, INO, ALDX: OCF Margin % Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's OCF Margin % falls into.


RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Rani Therapeutics Holdings's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-18.714/1.633
=-1,145.99 %

Rani Therapeutics Holdings's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.497/1.708
=-380.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -380.39% mean?
Rani Therapeutics Holdings (RANI) has a OCF Margin % of -380.39% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rani Therapeutics Holdings and its competitors. According to the industry distribution chart, Rani Therapeutics Holdings ranks #710 out of 959 companies in the Biotechnology industry, placing it in the top 74%.
Is Rani Therapeutics Holdings' OCF Margin % too high?
Rani Therapeutics Holdings' current OCF Margin % is -380.39%. Based on the distribution chart, Rani Therapeutics Holdings ranks #710 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' OCF Margin % compare to CGTX and INO?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #710 out of 959 companies for OCF Margin %. This places Rani Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current OCF Margin % is -380.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current OCF Margin % of -380.39%. The current OCF Margin % is -380.39%. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current OCF Margin % is -380.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price